Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy E Cerro-Herreros, I González-Martínez, N Moreno, J Espinosa-Espinosa, ... Molecular Therapy-Nucleic Acids 26, 174-191, 2021 | 14 | 2021 |
Musashi-2 contributes to myotonic dystrophy muscle dysfunction by promoting excessive autophagy through miR-7 biogenesis repression M Sabater-Arcis, A Bargiela, N Moreno, J Poyatos-Garcia, JJ Vilchez, ... Molecular Therapy-Nucleic Acids 25, 652-667, 2021 | 14 | 2021 |
Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screening P Soblechero-Martín, E Albiasu-Arteta, A Anton-Martinez, ... Scientific Reports 11 (1), 18188, 2021 | 12 | 2021 |
A study of the phenotypic variability and disease progression in Laing myopathy through the evaluation of muscle imaging N Muelas, M Frasquet, F Más‐Estellés, P Marti, L Martínez‐Vicente, ... European journal of neurology 28 (4), 1356-1365, 2021 | 7 | 2021 |
Dystrophinopathy Phenotypes and Modifying Factors in DMD Exon 45–55 Deletion J Poyatos‐García, P Martí, A Liquori, N Muelas, I Pitarch, L Martinez‐Dolz, ... Annals of Neurology 92 (5), 793-806, 2022 | 5 | 2022 |
CRISPR-Cas9 editing of a TNPO3 mutation in a muscle cell model of limb-girdle muscular dystrophy type D2 J Poyatos-García, Á Blázquez-Bernal, M Selva-Giménez, A Bargiela, ... Molecular Therapy-Nucleic Acids 31, 324-338, 2023 | | 2023 |
Deletion of exons 45 to 55 in the DMD gene: from the therapeutic perspective to the in vitro model J Poyatos-Garcia, P Soblechero-Martin, A Liquori, A Lopez-Martinez, ... bioRxiv, 2023.09. 13.557649, 2023 | | 2023 |
Estudio de la deleción espontánea de los exones 45–55 en el gen DMD y su aplicación como modelo de terapia génica. Análisis de factores condicionantes del fenotipo y estudio … J Poyatos García Estudio de la deleción espontánea de los exones 45–55 en el gen DMD y su …, 2023 | | 2023 |
A CRISPR/Cas9 edition protocol for human myoblasts to generate disease models P Soblechero-Martin, E Albiasu-Arteta, A Anton-Martinez, ... HUMAN GENE THERAPY 30 (11), A189-A189, 2019 | | 2019 |
P. 290Dystrophinopathic subjects with a specific mega-deletion of exons 45-55 in the DMD gene, as a template for CRISPR/Cas9 therapy in Duchenne muscular dystrophy J Poyatos-García, P Soblechero-Martín, E Albiasu-Arteta, ... Neuromuscular Disorders 29, S151-S152, 2019 | | 2019 |
P. 291Overcoming barriers to establish a CRISPR/Cas9 edition protocol for human myoblasts P Soblechero-Martin, E Albiasu-Arteta, J Poyatos-García, ... Neuromuscular Disorders 29, S152, 2019 | | 2019 |
Implication of the breakpoints position in patients with the macrodeletion of exons 45 to 55 in the DMD gene J Poyatos-Garcia, N Muelas Gomez, C Gomis, P Marti, I Pitarch, ... EUROPEAN JOURNAL OF NEUROLOGY 26, 693-693, 2019 | | 2019 |
Outcome of patients with sustained hyperCKemia after statin treatment N Muelas, P Marti, Y Pamblanco, C Gomis, R Vilchez, J Poyatos-Garcia, ... EUROPEAN JOURNAL OF NEUROLOGY 26, 251-251, 2019 | | 2019 |